Šalis: Naujoji Zelandija
kalba: anglų
Šaltinis: Medsafe (Medicines Safety Authority)
Ciprofloxacin hydrochloride 2.33mg equivalent to ciprofloxacin 0.2% w/v; Hydrocortisone 10mg equivalent to 1% w/v hydrocortisone; ; ; Ciprofloxacin hydrochloride 2.33mg equivalent to ciprofloxacin 0.2% w/v; Hydrocortisone 10mg equivalent to 1% w/v hydrocortisone
Novartis New Zealand Ltd
Ciprofloxacin hydrochloride 2.33 mg (= ciprofloxacin 0.2% w/v)
Ear drops
Active: Ciprofloxacin hydrochloride 2.33mg equivalent to ciprofloxacin 0.2% w/v Hydrocortisone 10mg equivalent to 1% w/v hydrocortisone Excipient: Benzyl alcohol Glacial acetic acid Lecithin Polysorbate 20 Polyvinyl alcohol Purified water Sodium acetate trihydrate Sodium chloride Active: Ciprofloxacin hydrochloride 2.33mg equivalent to ciprofloxacin 0.2% w/v Hydrocortisone 10mg equivalent to 1% w/v hydrocortisone Excipient: Benzyl alcohol Glacial acetic acid Lecithin Polysorbate 20 Polyvinyl alcohol Purified water Sodium acetate trihydrate Sodium chloride
Bottle, glass, 10 mL
Prescription
Prescription
Bayer AG
The treatment of acute bacterial external otitis caused by organisms susceptible to the action of ciprofloxacin, including Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter anitratus (baumannii), Stenotrophomonas maltophilia, Enterobacteriaceae, Enterococcus faecalis and Proteus mirabilis.
Package - Contents - Shelf Life: Bottle, glass, - 10 mL - 24 months from date of manufacture stored at or below 25°C protect from light. Do not refigerate 14 days opened stored at or below 25°C protect from light. Do not refrigerate
1998-03-20
Internal document code 1 cip080720cNZ based on DS cip080720iNZ CIPROXIN ® HC EAR DROPS _Ciprofloxacin and Hydrocortisone _ _ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU USE CIPROXIN HC EAR DROPS. This leaflet answers some common questions about Ciproxin HC Ear Drops. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available. You should ensure that you speak to your pharmacist or doctor to obtain the most up to date information on the medicine. You can also download the most up to date leaflet from www.medsafe.govt.nz. The updates may contain important information about the medicine and its use of which you should be aware. All medicines have risks and benefits. Your doctor has weighed the expected benefits of you using Ciproxin HC against the risks this medicine could have for you. The information in this leaflet applies to Ciproxin HC only. This information does not apply to similar products, even if they contain the same ingredients. If you have any concerns about using this medicine, ask your doctor or pharmacist. KEEP THIS LEAFLET WITH THE MEDICINE. WHAT CIPROXIN IS USED FOR Ciproxin HC Ear Drops contains two active ingredients; ciprofloxacin and hydrocortisone. Ciprofloxacin is a “fluoroquinolone” antibiotic which kills the bacteria causing the infection. Hydrocortisone is a corticosteroid that reduces the pain, redness and inflammation. Ciproxin HC Ear Drops are used to treat a condition called bacterial otitis externa, which is an infection of the outer ear caused by bacteria which may cause itching or pain. Before prescribing Ciproxin HC Ear Drops for you or your child, your doctor will have examined your ear and decided that Ciproxin HC Ear Drops is the right medicine. Your doctor may have prescribed it for another reason. Ciproxin HC Ear Perskaitykite visą dokumentą
Internal document code cip080720iNZ 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME CIPROXIN ® HC Ear Drops ciprofloxacin 0.2% and hydrocortisone 1%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ciproxin HC Ear Drops contain 23.3 mg ciprofloxacin hydrochloride (equivalent to ciprofloxacin 0.2 % w/v) and hydrocortisone 100 mg (1% w/v). Excipient with known effect Benzyl alcohol 9 mg in 1 mL as a preservative. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Ear drops. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS The treatment of acute bacterial external otitis caused by organisms susceptible to the action of ciprofloxacin, including _Pseudomonas aeruginosa, Staphylococcus _ _aureus, Acinetobacter anitratus (baumannii), Stenotrophomonas maltophilia,_ _Enterobacteriaceae_ , _Enterococcus faecalis_ and _Proteus mirabilis._ 4.2. DOSE AND METHOD OF ADMINISTRATION For children (aged two years and older) and adults, three drops of the suspension should be instilled into the affected ear twice daily for seven days. The bottle should be shaken well, immediately before use. The patient should tilt the head to one side with the affected ear upward and then the drops should be instilled. This position should be maintained for a minimum of 30 seconds to facilitate penetration of the drops into the external ear canal. Repeat, if necessary, for the opposite ear. Patient instructions for use/handling Remove the closure and put the dropper assembly in place on the bottle. Ciproxin HC Ear Drops is a ready to use when dropper assembly is placed on the bottle. Shake well immediately before using. Warm to room temperature prior to application. Avoid contaminating the dropper with material from the ear, fingers or other sources. Discard unused portion after therapy is completed. Keep all medicines out of the reach of children. Internal document code cip080720iNZ 2 4.3. CONTRAINDICATIONS Ciproxin HC Ear Drops are contraindicated in patients being treated for necrotizing malignant otitis externa. This condition, Perskaitykite visą dokumentą